sa国际传媒

Skip to content
Join our Newsletter

Health sa国际传媒 approves Pfizer-BioNTech's updated COVID-19 vaccine

Health sa国际传媒 approved Pfizer-BioNTech's updated COVID-19 vaccine on Tuesday, marking its third authorization of vaccine formulations that protect against the most recently circulating variants of the virus.
bb12e5d0228ac28c798f181964b65d7d2686b6e777998f03aabc9764a87e1730
Pfizer sa国际传媒 says Health sa国际传媒 has approved its updated COVID-19 vaccine that protects against one of the most recently circulating variants of the virus. Packaging for the Pfizer's updated COVID vaccine for ages 12 and up is shown in an August 2024 handout photo. THE CANADIAN PRESS/AP-HO, Pfizer, Steven Decroos, *MANDATORY CREDIT*

Health sa国际传媒 approved Pfizer-BioNTech's updated COVID-19 vaccine on Tuesday, marking its third authorization of vaccine formulations that protect against the most recently circulating variants of the virus.

Pfizer-BioNTech's mRNA vaccine, called Comirnaty, targets the KP.2 subvariant of Omicron, replacing the previous version that targeted the XBB.1.5 Omicron subvariant.

The approval of Comirnaty follows last week's authorization of Moderna's updated Spikevax mRNA vaccine and Novavax鈥檚 updated protein-based vaccine, Nuvaxovid.

Health sa国际传媒 recently asked provinces and territories to get rid of their older COVID-19 vaccines to ensure the most current vaccine will be used during this fall's respiratory virus season.

The timelines for when people can roll up their sleeves to get the new shots is up to the provinces and territories, Public Health Agency of sa国际传媒 spokesperson Anna Maddison said in an email last week.

"sa国际传媒 has secured sufficient supply of COVID-19 vaccines to meet provincial and territorial demand requirements for fall and winter 2024 vaccination campaigns," she said.

The Novavax vaccine targets the JN.1 subvariant, while the Pfizer and Moderna vaccines target the KP.2 subvariant. KP.2 is a sublineage of the JN.1 strain.

Pfizer and Moderna vaccines are approved for adults and for children six months of age and older.

Novavax's vaccine is approved for adults and for children 12 years and older. Nuvaxovid's product monograph says the vaccine has not yet been evaluated for safety and efficacy in children under 12.

In May, the National Advisory Committee on Immunization issued guidance for use of updated COVID-19 vaccines this fall if they were to be approved by Health sa国际传媒.

In that guidance, NACI strongly recommended updated COVID-19 vaccinations for all adults 65 and older, people living in long-term care and other group living settings, people with underlying conditions that put them at higher risk of severe illness, people from Indigenous and racialized communities, and those who are pregnant or who provide essential community services.

NACI said all other adults and children six months or older should also be eligible for an updated COVID-19 vaccination this fall.

According to the Public Health Agency of sa国际传媒's wastewater data, updated on Tuesday, COVID-19 viral activity is moderate on a national level, but some wastewater collection points in Yukon, British Columbia, Manitoba, New Brunswick and Newfoundland and Labrador have registered high levels of activity as of Sept. 8.

This report by The Canadian Press was first published Sept. 24, 2024.

Canadian Press health coverage receives support through a partnership with the Canadian Medical Association. CP is solely responsible for this content.

Nicole Ireland and Hannah Alberga, The Canadian Press